Expression of the steroid receptor RNA activator in human breast tumors

The expression of the recently described steroid receptor RNA activator (SRA) was measured by semiquantitative reverse transcription-PCR within 27 independent breast tumors, spanning a wide spectrum of grade and estrogen receptor (ER) and progesterone receptor (PR) levels. Subgroup analysis showed t...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1999-09, Vol.59 (17), p.4190-4193
Main Authors: LEYGUE, E, DOTZLAW, H, WATSON, P. H, MURPHY, L. C
Format: Article
Language:English
Subjects:
Biological and medical sciences
Breast Neoplasms - chemistry
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Chromosomes, Human, Pair 5
Female
Gynecology. Andrology. Obstetrics
Histone Acetyltransferases
Humans
Mammary gland diseases
Medical sciences
Nuclear Receptor Coactivator 1
Receptors, Estrogen - analysis
Receptors, Progesterone - analysis
Receptors, Steroid - genetics
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - analysis
SRA gene
steroid receptor RNA activator
Trans-Activators - analysis
Transcription Factors - analysis
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The expression of the recently described steroid receptor RNA activator (SRA) was measured by semiquantitative reverse transcription-PCR within 27 independent breast tumors, spanning a wide spectrum of grade and estrogen receptor (ER) and progesterone receptor (PR) levels. Subgroup analysis showed that SRA expression was similar in ER+/PR+ (median = 65.5, n = 8) and in ER-/PR- (median = 94.6, n = 5) tumors. Interestingly, SRA expression in these two subgroups was significantly (Mann-Whitney rank-sum test, P < 0.05) lower than that observed in ER+/PR- (median = 156.4, n = 6) and ER-/PR+ (median = 144.8, n = 8) tumors. A variant form of SRA, presenting a deletion of 203 bp within the SRA core sequence, was also observed in breast tumor tissues. The relative expression of this new SRA isoform correlated with tumor grade (Spearman coefficient r = 0.53, n = 27, P = 0.004). These data suggest that changes in the expression of SRA-related molecules occur during breast tumor progression.
ISSN:0008-5472
1538-7445